Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
The Ministry of Health, Labor and Welfare (MHLW) plans to ask medical societies and national medical centers to compile lists of “candidate drugs” likely to be subject to a new government scheme that combines publicly insured and uninsured therapies at…
To read the full story
Related Article
- Chuikyo Approves Draft Framework for Patient-Initiated Mixed Care; Will Establish Evaluation Council by Next Spring
October 2, 2015
- FY2016 Drug Pricing Reform
August 18, 2015
- FY2015 Survey on Generic Use to Get Underway, Results Out in Autumn
July 9, 2015
- Patient-Initiated Mixed Care Used Only When Compassionate Access Can’t Be Applied: Minister
April 28, 2015
- Most Cancer Drugs Would Cost Over 1 Million Yen a Month under Patient-Initiated Mixed Care: NCC
April 7, 2015
- PM Abe Promises to Introduce Patient-Initiated Mixed-Care System while Maintaining Universal Healthcare
January 30, 2015
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- Chuikyo OKs Patient-Initiated Mixed-Care System, Use of Investigational Drugs for Non-Enrollable Patients
November 7, 2014
- Chuikyo Begins Discussions on Patient-Initiated Mixed-Care System
October 24, 2014
- Govt Panel Says New Mixed-Care Scheme Is “Patient-Initiated” but Current System Isn’t
October 14, 2014
- PM Abe Vows to Forge New System to Accelerate Mixed Care
June 11, 2014
- Govt Deregulation Panel Pushes New System to Allow Mixed Care at Patient Request
March 31, 2014
REGULATORY
- Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
- MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
March 9, 2026
- Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…